Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate
affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the
calcium influx into the neurons), a drug used to treat Alzheimer´s disease, on the
progression of Amyotrophic Lateral Sclerosis (ALS). Memantine is added to riluzole (the
single drug approved to treat ALS).